Table 2. Clinical data.

Clinical data	Drug-naive	Treated	p	Co-infection with other pathogens (n = 318)
	(n = 234)	(n = 78)
CD4 count (median cells/µL)	315	338	NS	Hepatitis	176 (55.3%)
Viral load (median copies/ml (logVL))	29,950 (4.48)	15,800 (4.20)	NS	TB total	14 (4.4%)
Sero-conversion	6	2	NS	TB+HCV	12 (3.7%)
Age at diagnosis (years median ± S.E.M)	31.9±0.6	31.1±1.4	NS	Syphilisa total	10 (3.1%)
Time from diagnosis to genotyping (Months median ± S.E.M)	2.1±1.9	56.8±3.6	>0.001	Syphilis+HCV	8 (2.5%)
Time under treatment (Months median ± S.E.M)	NA	37.8±2.7	NA	TB+Syphilis+HCV	1 (0.3%)

The Table lists various clinical parameters, pertaining to drug-naive and treatment-failing individuals (the two left columns, respectively), and specifically regarding co-infection status (on the right).

^aInfectious syphilis (primary, secondary or early-latent) was defined by a positive VDRL test (Venereal Disease Research Laboratory Becton-Dickenson, Shannon, Ireland) as previously described [5]. Four individuals were in a primary or secondary phase and six were in late phase of the disease. Two of the ten (20%) were MSM, who comprised 15% of all A/AE-infected individuals. At least three acquired HIV in Israel.

cART – combination antiretroviral therapy; HCV – Hepatitis C virus; MSM – Men who have sex with men; NA – Not applicable; NS – Not significant; S.E.M – Standard error of mean; TB – Tuberculosis; VL – viral load.